Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy.

Author(s): Hesse UJ, DeDecker C, Houtmeyers P, Demetter P, Ceelen W, Pattyn P, Troisi R, deHemptinne B

Affiliation(s): Department of Surgery, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. uwe.uhesse@kbc-intern.de

Publication date & source: 2005-10, World J Surg., 29(10):1325-8.

Publication type: Randomized Controlled Trial

The aim of the present study was to evaluate the influence of low-dose perioperative octreotide on the prevention of complications (pancreatic fistula and general complications) in patients undergoing pancreatic surgery followed by pancreaticojejunostomy. A total of 105 patients were randomized to receive either octreotide 0.1 mg subcutaneously 3 times/day for a total of 7 days or no octreotide. The primary endpoints were the occurrence of a pancreatic fistula and or general complications, including extended length of hospital stay. There were 25 surgical draining procedures performed and 80 duodenopancreatectomies with or without preservation of the pylorus. In all, 25 (23.8%) of the patients were treated for chronic pancreatitis, 8 (7.6%) for benign tumoral disease, and 72 (68.6%) for carcinoma. All patients underwent pancreaticojejunostomy.